Rohto Seiyaku KK header image

Rohto Seiyaku KK

4527

Equity

ISIN JP3982400008 / Valor 763212

Tokyo Stock Exchange (2024-11-21)
JPY 2,745.00+0.99%

Rohto Seiyaku KK
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Rohto Seiyaku KK, also known as Rohto Pharmaceutical Co., Ltd., is a Japanese company engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company focuses on creating innovative solutions for various health issues, including urinary incontinence. Rohto's product portfolio spans over-the-counter medications, skincare products, and eye care solutions, catering to both domestic and international markets. With a commitment to advancing healthcare, Rohto continually invests in research and development to introduce new values, products, and business ventures within the healthcare sector.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (14.08.2024):

Revenue Growth

Rohto Seiyaku KK reported a significant increase in net sales for the first quarter of the fiscal year ending March 31, 2025. The company achieved net sales of ¥68,356 million, up from ¥61,171 million in the same period the previous year. This growth was driven by the recovery in economic activity, increased inbound demand, and favorable product proposals.

Operating Income

Despite a rise in the cost of sales ratio, Rohto Seiyaku KK managed to increase its operating income to ¥11,790 million in the first quarter of FY3/2025, compared to ¥11,292 million in the same quarter of the previous year. This was achieved through effective utilization of selling, general, and administrative expenses.

Profit Decline

Rohto Seiyaku KK experienced a decrease in profit attributable to owners of the parent, which fell to ¥8,482 million in the first quarter of FY3/2025 from ¥9,090 million in the same period the previous year. The decline was primarily due to extraordinary losses despite the increase in net sales and operating income.

Segment Performance in Asia

In the Asian market, Rohto Seiyaku KK saw a significant increase in both sales and profits. Sales in Asia reached ¥18,091 million, up 13.8% year-over-year, while operating profit surged by 51.2% to ¥4,320 million. This growth was attributed to strong sales in Indonesia, Hong Kong, Taiwan, and a recovery in China and Vietnam.

Dividend Increase

Rohto Seiyaku KK announced an increase in its annual dividend from 30 yen to 33 yen, reflecting the company's strong financial performance and commitment to returning value to its shareholders. This decision was made in light of the positive outlook for the fiscal year ending March 31, 2025.

Summarized from source with an LLMView Source

Key figures

-11.0%1Y
63.2%3Y
59.8%5Y

Performance

33.9%1Y
32.3%3Y
30.4%5Y

Volatility

Market cap

4196 M

Market cap (USD)

Daily traded volume (Shares)

1,109,600

Daily traded volume (Shares)

1 day high/low

2766.5 / 2710.5

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Oncopeptides AB
Oncopeptides AB Oncopeptides AB Valor: 35671972
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.48%SEK 1.51
QuidelOrtho Corporation
QuidelOrtho Corporation QuidelOrtho Corporation Valor: 119356965
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.09%USD 37.89
Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings Inc Zimmer Biomet Holdings Inc Valor: 1262932
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.80%USD 108.40
dentalcorp Holdings Ltd
dentalcorp Holdings Ltd dentalcorp Holdings Ltd Valor: 111405816
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.18%CAD 9.24
DocMorris Ltd
DocMorris Ltd DocMorris Ltd Valor: 4261528
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-6.11%CHF 28.90
Savaria Corp
Savaria Corp Savaria Corp Valor: 1385257
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.80%CAD 22.81
Sienna Senior Living Inc
Sienna Senior Living Inc Sienna Senior Living Inc Valor: 28093100
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.24%CAD 17.03
WELL Health Technologies Corp
WELL Health Technologies Corp WELL Health Technologies Corp Valor: 42769021
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.58%CAD 5.17
agilon health inc
agilon health inc agilon health inc Valor: 110653729
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
6.59%USD 1.78
Terveystalo Oyj
Terveystalo Oyj Terveystalo Oyj Valor: 37893402
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.61%EUR 9.80